PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-9.83%
Cash & equivalents declining -9.83% while Medical - Pharmaceuticals shows 0.80% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-9.83%
Below half the Medical - Pharmaceuticals median of 1.98% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
-20.00%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
0.71%
Inventory growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
1.27%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-2.34%
Below half the Medical - Pharmaceuticals median of 2.90%. Jim Chanos would question if the company faces working capital strain.
2.51%
PP&E growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.54%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
-7.12%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-7.12%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
0.64%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
-0.64%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
0.64%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
2.29%
≥ 1.5x the Medical - Pharmaceuticals median of 1.17%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
0.86%
Below half the Medical - Pharmaceuticals median of 2.10%. Jim Chanos might see potential stagnation or distress vs. peers.
-0.41%
Payables growth below half of Medical - Pharmaceuticals median of 0.19%. Joel Greenblatt sees more conservative payables management vs. peers.
88.33%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-47.20%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-47.00%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
-10.53%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-0.20%
Below half Medical - Pharmaceuticals median of 3.09%. Joel Greenblatt sees more conservative short-term leverage than peers.
-8.24%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.13%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-5.77%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-0.88%
Below half Medical - Pharmaceuticals median of 0.82%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
3.50%
Below half Medical - Pharmaceuticals median of -0.93%. Jim Chanos suspects poor profitability or large dividend drains.
8.06%
Above 1.5x Medical - Pharmaceuticals median 3.24%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
3.21%
≥ 1.5x Medical - Pharmaceuticals median of 1.77%. Joel Greenblatt sees stronger equity growth vs. peers.
0.86%
Below half Medical - Pharmaceuticals median of 2.25%. Jim Chanos suspects a major slowdown or distress.
0.64%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
20.57%
Above 1.5x Medical - Pharmaceuticals median of 0.12%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
69.14%
Above 1.5x Medical - Pharmaceuticals median 4.30%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.